BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Barr JL, Zhao P, Brailoiu GC, Brailoiu E. Choline-Sigma-1R as an Additional Mechanism for Potentiation of Orexin by Cocaine. Int J Mol Sci 2021;22:5160. [PMID: 34068146 DOI: 10.3390/ijms22105160] [Reference Citation Analysis]
2 Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 2020;43:zsaa080. [PMID: 32303763 DOI: 10.1093/sleep/zsaa080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
3 Holsboer F, Ising M. Hypothalamic stress systems in mood disorders. Handb Clin Neurol 2021;182:33-48. [PMID: 34266603 DOI: 10.1016/B978-0-12-819973-2.00003-4] [Reference Citation Analysis]
4 Xu S, Cui Y, Shen J, Wang P. Suvorexant for the prevention of delirium: A meta-analysis. Medicine (Baltimore) 2020;99:e21043. [PMID: 32791676 DOI: 10.1097/MD.0000000000021043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
5 Elam HB, Perez SM, Donegan JJ, Lodge DJ. Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis. Transl Psychiatry 2021;11:114. [PMID: 33558469 DOI: 10.1038/s41398-021-01235-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Vasiliu O. Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents. Front Pharmacol 2022;13:884143. [DOI: 10.3389/fphar.2022.884143] [Reference Citation Analysis]
7 Kaufmann P, Ort M, Golor G, Kornberger R, Dingemanse J. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313. Prog Neuropsychopharmacol Biol Psychiatry 2021;108:110166. [PMID: 33159976 DOI: 10.1016/j.pnpbp.2020.110166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Han Y, Cao L, Yuan K, Shi J, Yan W, Lu L. Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse. Neurosci Bull . [DOI: 10.1007/s12264-022-00872-3] [Reference Citation Analysis]
9 Vázquez-León P, Miranda-Páez A, Chávez-Reyes J, Allende G, Barragán-Iglesias P, Marichal-Cancino BA. The Periaqueductal Gray and Its Extended Participation in Drug Addiction Phenomena. Neurosci Bull 2021. [PMID: 34302618 DOI: 10.1007/s12264-021-00756-y] [Reference Citation Analysis]
10 Chrobok L, Jeczmien-Lazur JS, Bubka M, Pradel K, Klekocinska A, Klich JD, Ridla Rahim A, Myung J, Kepczynski M, Lewandowski MH. Daily coordination of orexinergic gating in the rat superior colliculus-Implications for intrinsic clock activities in the visual system. FASEB J 2021;35:e21930. [PMID: 34533886 DOI: 10.1096/fj.202100779RR] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chellappa SL, Aeschbach D. Sleep and anxiety: From mechanisms to interventions. Sleep Med Rev 2021;61:101583. [PMID: 34979437 DOI: 10.1016/j.smrv.2021.101583] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry 2020;11:595584. [PMID: 33424664 DOI: 10.3389/fpsyt.2020.595584] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
13 Roveta F, Marcinnò A, Cremascoli R, Priano L, Cattaldo S, Rubino E, Gallo E, Boschi S, Mauro A, Rainero I. Increased orexin A concentrations in cerebrospinal fluid of patients with behavioural variant frontotemporal dementia. Neurol Sci 2021. [PMID: 33904007 DOI: 10.1007/s10072-021-05250-x] [Reference Citation Analysis]
14 Uchiyama M, Kambe D, Imadera Y, Kajiyama Y, Ogo H, Uchimura N. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study. Psychopharmacology (Berl) 2022. [PMID: 35296912 DOI: 10.1007/s00213-022-06089-6] [Reference Citation Analysis]
15 [DOI: 10.1101/2021.02.20.432093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]